FDA Grants Accelerated Approval to Neladalkib for Pretreated ALK-Positive Lung Cancer

A Next Step After ALK Drugs Fail

Most ALK-positive lung cancers eventually learn to grow despite the targeted drugs that hold them back. For patients at that point, the US Food and Drug Administration has granted accelerated approval to neladalkib, sold as Nelkarmi, ten days before its scheduled decision date.

Blood test.
Blood test. Image credit: Piqsels, free public domain licence

Key Takeaways

  • Neladalkib is cleared for adults with advanced ALK-positive non-small cell lung cancer who previously took alectinib, or two or more ALK inhibitors plus platinum chemotherapy.
  • In the ALKOVE-1 trial, 49% of patients treated after alectinib alone responded, and 32% responded after two or more ALK drugs and chemotherapy.
  • The FDA acted on 17 November, ahead of its 27 November target date.

Who Can Receive It

The approval covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. Patients must have received alectinib as their only prior ALK tyrosine kinase inhibitor, or two or more ALK inhibitors together with platinum-based chemotherapy.

Neladalkib is an ALK-selective kinase inhibitor taken as a 150 mg tablet once a day. Its developer, Nuvalent, designed it to reach the brain and to stay active against resistance mutations, including G1202R, that blunt earlier drugs.

What the Trial Showed

The decision rests on ALKOVE-1, a single-arm, open-label phase 1/2 trial with several patient groups. It had no comparison arm.

Among 67 patients whose only prior ALK drug was alectinib, the confirmed overall response rate was 49%. In that group, 76% of responders stayed in response for at least six months and 52% for at least a year.

Among 155 patients who had two or more ALK inhibitors and platinum chemotherapy, 32% responded. Of those responders, 69% kept their response for six months or longer and 51% for a year or longer.

Side Effects and Warnings

The most common side effects, seen in at least one in five patients, were liver toxicity, musculoskeletal pain, constipation, taste changes, nerve damage in the hands and feet, swelling and fatigue.

The label carries warnings for liver, kidney and eye toxicity, raised creatine phosphokinase levels and harm to an unborn baby. The FDA reviewed the application under priority review, and neladalkib also holds breakthrough therapy and orphan drug designations.

Why Resistance Drives Lung Cancer Research

ALK-positive disease makes up a small share of lung cancers, but it often affects younger people and non-smokers. Patients can live for years on targeted pills, which makes resistance the main hurdle. Under an accelerated approval, continued marketing usually depends on further trials confirming the benefit. The approval sets clear treatment-history requirements, which places neladalkib after current standard drugs rather than as a first option for now.

The drug also gives GSK an early return on its oncology push. The British drugmaker agreed in June to buy Nuvalent for $10.6 billion, mainly for neladalkib and its sister ROS1 drug, zidesamtinib. The FDA has had a busy month in oncology, approving a giredestrant combination for breast cancer while rejecting Summit's ivonescimab for lung cancer over survival data. Earlier, it used the same fast-track route for dostarlimab in rectal cancer.

Written by Alius Noreika